Pharmacological treatment of irritable bowel syndrome - From concept to sales

European Journal of Surgery, Supplement

Volumn 168, Issue 587, 2002, Pages 10-15

  Kamm, Michael A ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

Alosetron; Antidepressant; Cisapride; Drug treatment; Irritable bowel syndrome; Serotonin; Tegaserod

Indexed keywords

ALOSETRON; ANTIDEPRESSANT AGENT; BUSPIRONE; CISAPRIDE; GRANISETRON; LOPERAMIDE; OCTREOTIDE; ONDANSETRON; PRUCALOPRIDE; SEROTONIN 1 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SUMITRIPTAN; TEGASEROD; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; CARBOLINE DERIVATIVE; GASTROINTESTINAL AGENT; INDOLE DERIVATIVE; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ACCOMMODATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DYSPEPSIA; FUNCTIONAL DISEASE; GASTROINTESTINAL DISEASE; GOVERNMENT; HEALTH CARE; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; INTERNET; IRRITABLE COLON; ISCHEMIC COLITIS; MEDICAL RESEARCH; MOTOR PERFORMANCE; MULTICENTER STUDY; NONHUMAN; PERISTALSIS; PHYSIOLOGY; PRESSURE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QT INTERVAL; QUALITY OF LIFE; SECRETION; SENSATION; SEROTONIN METABOLISM; STRESS; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG INDUSTRY; DRUG POTENTIATION; ECONOMICS; REVIEW;

ANTIDEPRESSIVE AGENTS; BENZOFURANS; CARBOLINES; CISAPRIDE; CONSTIPATION; DRUG INDUSTRY; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; RECEPTORS, SEROTONIN, 5-HT3; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0036958169     PISSN: 1102416X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Camilleri M, Nortcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-1040.
2. Camilleri M. Tegaserod. Aliment Pharmacol Ther 2001; 15: 277-289.
3. Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984; 25: 168-173.
4. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1994; 29: 239-247.
5. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8: 409-416.
6. Delvaux M, Louvel D, Mamet J-P, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-855.
7. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998; 42: 511-516.
8. Emmanuel AV, Nicholls T, Roy AJ, Antonelli K, Kamm MA. Prucalopride improves colonic transit and stool frequency in patients with slow and normal transit constipation. Gastroenterology 2000; 118: A846.
9. Federal Drug Administration (USA) website, http://www.fda.gov/medwatxh/safety
10. Ferriman A. UK licence for cisapride suspended. BMJ 2000; 321: 259.
11. Fischler B, De Gucht V, Tack J, Janssens J. Psychosocial and psychopathological correlates of hypersensitivity to gastric distension in functional dyspepsia. Gastroenterology 1999; 116: A163.
12. Fischler B, De Gucht V, Tack J, Janssens J. Relationship between job stress and physiopathological mechanisms in functional dyspepsia. Gastroenterology 1999; 116: A163.
13. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 (suppl 2): 15-30.
14. 3 antagonism (Ondansetron). Digestion 1996; 57: 478-483.
15. Kamm MA. The role of psychosocial factors in functional gut disease. Eur J Surg 1998; 164: 37-40.
16. Kamm MA. Entry criteria for drug trials of irritable bowel syndrome. Am J Med 1999; 107: 51S-58S.
17. Lefkowitz M, Ligozio G, Heggland J, Dunger-Baldauf C, Ruegg PC. Tegaserod is well tolerated in patients with diarrhoea-predominant irritable bowel syndrome. Gut 2000; 47 (suppl 3): A217.
18. Miura M, Lawson DC, Clary EM, et al. Central modulation of rectal-distension induced blood pressure changes by alosteron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 20-24.
19. Tack J, Piessevaux H, Coulie B, Janssens J. Influence of a fundus-relaxing drug on meal-related symptoms in dyspeptic patients with hyper-sensitivity to gastric distension. Gastroenterology 1999; 116: A324.
20. Tack J, Piessevaux H, Coulie B, Fischler B, De Gucht V, Janssens J. A placebo-controlled trial of buspirone, a fundus-relaxing drug, in functional dyspepsia: effect on symptoms and gastric sensory and motor function. Gastroenterology 1999; 116: A325.
21. Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosteron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 403-407.